EU Rejects Cymbalta For Fibromyalgia Treatment

Law360, New York (October 24, 2008, 12:00 AM EDT) -- In a blow to Eli Lilly & Co., the European Union's drug-regulating body has recommended against allowing the pharmaceutical giant to market Cymbalta as a fibromyalgia treatment after finding that the benefits of the drug – which is already approved in Europe for depression and anxiety – in the treatment of the disease do not outweigh its risks.

The European Medicines Agency's Committee for Medicinal Products for Human Use said Thursday it had adopted a negative opinion recommending the refusal of a change to the marketing...
To view the full article, register now.